These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33587572)

  • 1. Lemborexant (Dayvigo) for the Treatment of Insomnia.
    Rhodes MA
    Am Fam Physician; 2021 Feb; 103(4):241-242. PubMed ID: 33587572
    [No Abstract]   [Full Text] [Related]  

  • 2. Lemborexant (Dayvigo) for insomnia.
    Med Lett Drugs Ther; 2020 Jun; 62(1601):97-100. PubMed ID: 32724021
    [No Abstract]   [Full Text] [Related]  

  • 3. [Preclinical and clinical efficacy of orexin receptor antagonist Lemborexant (Dayvigo
    Koebisu M; Koyama N; Nishida M; Muramoto K
    Nihon Yakurigaku Zasshi; 2021; 156(2):114-119. PubMed ID: 33642529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials.
    Moline M; Zammit G; Yardley J; Pinner K; Kumar D; Perdomo C; Cheng JY
    Postgrad Med; 2021 Jan; 133(1):71-81. PubMed ID: 33119423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.
    McElroy H; O'Leary B; Adena M; Campbell R; Monfared AAT; Meier G
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1296-1308. PubMed ID: 34121443
    [No Abstract]   [Full Text] [Related]  

  • 6. Lemborexant for the Treatment of Insomnia: Direct and Indirect Comparisons With Other Hypnotics Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.
    Citrome L; Juday T; Frech F; Atkins N
    J Clin Psychiatry; 2021 Jun; 82():. PubMed ID: 34077032
    [No Abstract]   [Full Text] [Related]  

  • 7. Pilot Study of Lemborexant for Insomnia in Cancer Patients with Delirium.
    Terada T; Hirayama T; Sadahiro R; Wada S; Nakahara R; Matsuoka H
    J Palliat Med; 2022 May; 25(5):797-801. PubMed ID: 35099287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder.
    Chepke C; Jain R; Rosenberg R; Moline M; Yardley J; Pinner K; Kumar D; Perdomo C; Filippov G; Atkins N; Malhotra M
    Postgrad Med; 2022 Apr; 134(3):316-325. PubMed ID: 35254948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation.
    Beuckmann CT; Ueno T; Nakagawa M; Suzuki M; Akasofu S
    Sleep; 2019 Jun; 42(6):. PubMed ID: 30923834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of SAMP8 Mice as a Model for Sleep-Wake and Rhythm Disturbances Associated with Alzheimer's Disease: Impact of Treatment with the Dual Orexin (Hypocretin) Receptor Antagonist Lemborexant.
    Beuckmann CT; Suzuki H; Musiek ES; Ueno T; Sato T; Bando M; Osada Y; Moline M
    J Alzheimers Dis; 2021; 81(3):1151-1167. PubMed ID: 33843668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lemborexant: First Approval.
    Scott LJ
    Drugs; 2020 Mar; 80(4):425-432. PubMed ID: 32096020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.
    Murphy P; Moline M; Mayleben D; Rosenberg R; Zammit G; Pinner K; Dhadda S; Hong Q; Giorgi L; Satlin A
    J Clin Sleep Med; 2017 Nov; 13(11):1289-1299. PubMed ID: 29065953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lemborexant, an orexin receptor antagonist sedative-hypnotic: Is it useful for insomnia in psychiatric disorders?
    Keks NA; Hope J
    Australas Psychiatry; 2022 Aug; 30(4):530-532. PubMed ID: 35491942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: A randomized, double-blind, placebo-controlled, crossover study.
    Cheng JY; Filippov G; Moline M; Zammit GK; Bsharat M; Hall N
    J Sleep Res; 2020 Aug; 29(4):e13021. PubMed ID: 32187781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory Safety of Lemborexant in Healthy Subjects: A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Crossover Study.
    Cheng JY; Moline M; Zammit GK; Filippov G; Bsharat M; Hall N
    Clin Drug Investig; 2021 May; 41(5):449-457. PubMed ID: 33723806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of lemborexant 5 mg versus 10 mg for the treatment of insomnia: a systematic review.
    Habiba U; Waseem R; Shaikh TG; Waseem S; Ahmed SH; Asghar MS
    Neurol Sci; 2023 May; 44(5):1533-1541. PubMed ID: 36633778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suvorexant (Belsomra) for insomnia.
    Med Lett Drugs Ther; 2015 Mar; 57(1463):29-31. PubMed ID: 25719996
    [No Abstract]   [Full Text] [Related]  

  • 18. Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder.
    Lalovic B; Majid O; Aluri J; Landry I; Moline M; Hussein Z
    J Clin Pharmacol; 2020 Dec; 60(12):1642-1654. PubMed ID: 32666570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of the Efficacy and Safety of Lemborexant, a Dual Receptor Orexin Antagonist (DORA), in the Treatment of Adults With Insomnia Disorder.
    Waters K
    Ann Pharmacother; 2022 Feb; 56(2):213-221. PubMed ID: 34078141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New pharmacologic agents for insomnia and hypersomnia.
    Earl DC; Van Tyle KM
    Curr Opin Pulm Med; 2020 Nov; 26(6):629-633. PubMed ID: 32890017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.